Trial site
Clinical Research Alliance
Westbury, New York 11590, United StatesNot linked to an institution yet
- 7running trials
- 2closed trials
The trials here
What the 9 trials at this site are about, from their registry records.
- Phase
- Phase 35 trials
- Phase 11 trial
- Phase 1/21 trial
- Phase 21 trial
- Phase 2/31 trial
- Status
- Recruiting4 trials
- Active, not recruiting3 trials
- Terminated1 trial
- Withdrawn1 trial
- Lead sponsor
- Hoffmann-La Roche2 trials
- Bristol-Myers Squibb1 trial
- Daiichi Sankyo1 trial
- Eli Lilly and Company1 trial
- Gilead Sciences1 trial
- and 3 more
Running trials
Recruiting
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
NCT07310420· Phase 1· TerSera Therapeutics LLC· Source
Contact: Jonathan Goldberg, MD
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· Phase 3· Daiichi Sankyo· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Jonathan Goldberg, Site 0295
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221· Phase 1/2· Revolution Medicines, Inc.· Source
Contact: Revolution Medicines
Active, not recruiting
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567· Phase 3· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error